In Week of Mar 28, 2026, Senores Pharmaceuticals Ltd (Pharma - API) is outperforming Nifty 500 with +8.4% relative strength. Fundamentals: Average.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Mar 28, 2026
What: 56 new products approved in Q3 bringing total to 450 registered products with 850+ under registration
Impact: +₹120 Cr revenue
“During this quarter, we received approval of 56 new products, bringing our total portfolio of 450 registered products as of December 2025. Additionally, more than 850 products are currently under registration.”
What: Emerging markets business achieved highest-ever quarterly revenue and EBITDA while turning cash flow positive
Impact: +₹38 Cr revenue
“Importantly, the business is now cash-flow positive as well. We achieved our highest-ever quarterly revenue, EBITDA, and PAT in the emerging market business in Q3.”
What: Management confident of sustaining or improving 40% gross margins in US business
“Management is confident of sustaining or slightly improving the 40% gross margins in the US business and pushing emerging market EBITDA margins toward 20% by FY27.”
Earnings deceleration risks from management commentary
Trigger: Launch delays beyond 6-8 quarters
Impact: -200 bps margin impact
Management view: Pipeline: There is a significant backlog of 28 approved ANDAs that are yet to be launched, providing clear revenue visibility for the next 6-8 quarters.
Monitor: Quarterly product launch count
Trigger: New regulatory barriers in emerging markets
Impact: -300 bps margin impact
Management view: Registrations: A massive influx of approvals occurred, with 56 new products approved in Q3 alone, bringing the total registered portfolio to 450 products.
Monitor: Quarterly approval rate in emerging markets
Key quotes from recent conference calls
“Our nine-month results are in line with or slightly ahead of our annual guidance, and we remain confident of achieving our FY26 targets of 50% of top-line growth and 100% of PAT growth — Swapnil”
“We achieved our highest-ever quarterly revenue, EBITDA, and PAT in the emerging market business in Q3. Importantly, the business is now cash-flow positive as well. — Management”
“During this quarter, we received approval of 56 new products, bringing our total portfolio of 450 registered products as of December 2025. Additionally, more than 850 products are currently under registration. — Management”
“Management is confident of sustaining or slightly improving the 40% gross margins in the US business and pushing emerging market EBITDA margins toward 20% by FY27. — Management”
Forward-looking targets from management for FY26
Revenue Growth Target
50%
Implied PAT Growth
100%
OPM Guidance
30%
Key Milestones
• 50% top-line growth for FY26
• 100% PAT growth for FY26
• $16-18 million revenue from acquired entity in FY27
• 170-180 Crores revenue from emerging markets next year
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +70% | +80% | Stable |
| PAT (Net Profit) | +113% | +80% | Stable |
| OPM | 31.0% | +600 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 28, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Senores Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Senores Pharmaceuticals Ltd's profit is growing with an stable trend.
Senores Pharmaceuticals Ltd's revenue growth trend is stable.
Senores Pharmaceuticals Ltd's operating margin is volatile.
Senores Pharmaceuticals Ltd's long-term compounding rates
Senores Pharmaceuticals Ltd's earnings growth is stable with positive momentum on a sequential basis.
Senores Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Senores Pharmaceuticals Ltd appears fairly valued based on our fair value analysis.
Senores Pharmaceuticals Ltd's current PE ratio is 35.7x.
Senores Pharmaceuticals Ltd's current PE is 35.7x.
Senores Pharmaceuticals Ltd's price-to-book ratio is 4.5x.
Senores Pharmaceuticals Ltd is rated Average with a fundamental score of 41.73/100. This score is calculated from objective financial metrics
Senores Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Senores Pharmaceuticals Ltd's return ratios over recent years
Senores Pharmaceuticals Ltd's operating cash flow is negative (FY2025).
Senores Pharmaceuticals Ltd currently does not pay a significant dividend (yield 0.00%).
Senores Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
Senores Pharmaceuticals Ltd's promoter holding has increased recently.
Senores Pharmaceuticals Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Senores Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Senores Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Senores Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26, Senores Pharmaceuticals Ltd's management highlighted
Senores Pharmaceuticals Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why Senores Pharmaceuticals Ltd may be worth studying
Senores Pharmaceuticals Ltd investment thesis summary:
Senores Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
